• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Quantum-Si Presents its Vision to Transform Genomics and Proteomics Research at ASHG 2023

    10/31/23 8:00:00 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials
    Get the next $QSI alert in real time by email

    Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced it will showcase next-generation benchtop protein sequencing instrument, Platinum™, and the Company's vision to transform genomics and proteomics research, at the American Society of Human Genetics (ASHG) conference, in Washington, D.C., November 1-5.

    "Platinum, stands as a groundbreaking advancement in next-generation protein sequencing™ moving the field beyond the limitations posed by mass spectrometry and immunoassays. This robust tool is a solution, enabling precise, single-molecule resolution," remarked Quantum-Si Chief Executive Officer Jeff Hawkins. He continued, "Platinum is crucial in taking genomic datasets to the next level, enabling subsequent analysis of proteins that can unveil genome-to-proteome links that help to predict phenotype. Platinum will become an essential multi-omics research tool that is missing in today's workflows."

    Quantum-Si will showcase Platinum's capabilities at Booth #115, where Chief Commercial Officer Grace Johnston, Ph.D., and Jeff Hawkins will be available to discuss the technology and the vital significance of next-generation protein sequencing and proteomics.

    Additionally, on Thursday, November 2, at 4:30 p.m., Quantum-Si scientists will present: Unleashing Next-generation Protein Sequencing™ with Platinum™: How it will Transform Genomics and Proteomics Research. They will evaluate the challenges associated with existing proteomics technologies and how Platinum overcomes them.

    Platinum is the world's first next-generation single-molecule protein sequencing platform that uses proprietary recognizers to identify proteins and amino acids using kinetic binding signatures. Its elegant design and simple workflow enable broad-scale access to proteomic data, for every scientist, everywhere, making it a groundbreaking platform for the future of proteomics research. With its small benchtop design and low price-point, Platinum is poised to accelerate breakthroughs across scientific disciplines, from drug discovery to biotech, and help people live healthier and longer lives.

    About Quantum-Si Inc.

    Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com.

    Forward Looking Statements This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; our ongoing leadership transition; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the commercialization and adoption of the Company's existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company's commercialized PlatinumTM protein sequencing instrument and the Company's other products once commercialized; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties described under "Risk Factors" in the Company's Annual Report for the fiscal year ended December 31, 2022, and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231031381818/en/

    Get the next $QSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QSI

    DatePrice TargetRatingAnalyst
    2/7/2025$3.75Buy
    Alliance Global Partners
    12/8/2023$3.00Buy
    H.C. Wainwright
    9/25/2023$3.50 → $2.00Buy → Hold
    Canaccord Genuity
    10/20/2021$13.00Buy
    Canaccord Genuity
    More analyst ratings

    $QSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Hawkins Jeffrey Alan sold $32,846 worth of shares (23,707 units at $1.39), decreasing direct ownership by 0.89% to 2,646,716 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      3/24/25 6:48:37 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • General Counsel & Corp. Secr. Lapointe Christian sold $6,783 worth of shares (4,896 units at $1.39), decreasing direct ownership by 0.50% to 983,480 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      3/24/25 6:42:56 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Chief Financial Officer Keyes Jeffry R. sold $11,951 worth of shares (8,626 units at $1.39), decreasing direct ownership by 0.72% to 1,188,194 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      3/24/25 6:34:27 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $QSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Keyes Jeffry R. bought $43,465 worth of shares (50,000 units at $0.87), increasing direct ownership by 13% to 446,820 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      8/13/24 6:01:25 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • President & CEO Hawkins Jeffrey Alan bought $21,272 worth of shares (25,000 units at $0.85), increasing direct ownership by 3% to 1,003,757 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      8/13/24 6:01:28 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Director Kummeth Charles R. bought $148,459 worth of shares (170,000 units at $0.87), increasing direct ownership by 92% to 355,000 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      8/13/24 6:01:24 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $QSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners initiated coverage on Quantum-Si with a new price target

      Alliance Global Partners initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $3.75

      2/7/25 8:29:38 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • H.C. Wainwright initiated coverage on Quantum-Si with a new price target

      H.C. Wainwright initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $3.00

      12/8/23 7:55:31 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Quantum-Si from Buy to Hold and set a new price target of $2.00 from $3.50 previously

      9/25/23 9:04:14 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $QSI
    Financials

    Live finance-specific insights

    See more
    • Quantum-Si to Report First Quarter 2025 Financial Results on May 15, 2025

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced that it will report financial results for the first quarter 2025 on Thursday, May 15, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in number and personali

      4/24/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si Reports Fourth Quarter and Full Year 2024 Financial Results

      Achieves First Quarterly Revenue Over $1 Million Completes Capital Raises of $86 Million Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the fourth quarter and full year ended December 31, 2024. Press Release Highlights Reported revenue of $1.2 million for the fourth quarter of 2024 and $3.1 million for the full year 2024 (representing a 183% full year-over-year growth) Raised capital of over $86 million between the fourth quarter of 2024 and first week of 2025 (extending cash runway into the second half of 2027) Announced the launch of Platinum® Pro in January 2025, with shipp

      3/3/25 4:05:00 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 3, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in numbe

      2/12/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $QSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Quantum-Si Incorporated

      SC 13D/A - Quantum-Si Inc (0001816431) (Subject)

      9/17/24 4:24:56 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Quantum-Si Incorporated

      SC 13G/A - Quantum-Si Inc (0001816431) (Subject)

      6/28/24 5:16:32 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G filed by Quantum-Si Incorporated

      SC 13G - Quantum-Si Inc (0001816431) (Subject)

      2/13/24 9:41:18 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $QSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Quantum-Si to Report First Quarter 2025 Financial Results on May 15, 2025

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced that it will report financial results for the first quarter 2025 on Thursday, May 15, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in number and personali

      4/24/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si Begins Shipping Platinum® Pro, Advancing Accessibility in Next-Gen Protein Sequencing™

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, announces the start of shipments for its latest benchtop sequencer, Platinum® Pro. This groundbreaking instrument offers protein analysis with single-molecule precision, aiming to make Next-Gen Protein Sequencing™ more accessible to laboratories worldwide. Platinum Pro delivers a comprehensive solution for sequencing and analyzing proteins through a simple, integrated workflow. Building upon the foundation of innovation established by the original Platinum, the new system introduces advanced features tailored to the evolving needs of researchers and biopharmaceutical customers. Key

      3/26/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si to Participate in DNAnexus Webinar on Large Scale Proteomics in Multi-Omics Research

      Validate multi-omics findings at the single-molecule level with Next-Gen Protein Sequencing™ Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, announces participation in an upcoming DNAnexus webinar focused on the role of proteomics in multi-omics research. This discussion will explore how the integration of proteomics data with other omics datasets is driving new discoveries in disease research, including cancer. When: March 25, 2025, at 8 a.m. PT/11 a.m. ET Attendees will learn about: The growing impact of proteomics in multi-omics analysis Applications for cancer and other disease research Technologies and strategies fo

      3/20/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $QSI
    Leadership Updates

    Live Leadership Updates

    See more
    • Quantum-Si Appoints Former Bio-Techne President and CEO, Chuck Kummeth, to serve as independent Chairman of the Board of Directors

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced the appointment of Charles ("Chuck") Kummeth to the role of independent Chairman of the Board, effective May 27, 2024. Mr. Kummeth has over 35 years of leadership experience in Life Sciences most recently as President and CEO of Bio-Techne. During Mr. Kummeth's tenure at Bio-Techne, he oversaw tremendous growth across all aspects of the business including annual revenue growth from $300M to over $1.1B, growth in the employee base from 800 to over 3,000, and the successful execution of 19 acquisitions, all while maintaining a 35% or better EBITDA level. Under Mr. Ku

      5/30/24 4:05:00 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si Appoints Former Illumina and Cisco Systems Executive, Paula Dowdy, to its Board of Directors

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced the appointment of Paula Dowdy, a senior executive with more than 35 years of experience across life sciences, enterprise software, and technology industries, to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321183506/en/Paula Dowdy (Photo: Business Wire) Ms. Dowdy currently serves on the Board of Directors for SPT Labtech, a world leading lab automation tools company based in the UK and is an advisor at EQT Life Sciences, one of Europe's leading investors targeting innovative

      3/21/24 4:05:00 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si Introduces World's First Next-Generation Protein Sequencer™ in Japan with Addition of New Distributor

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it has entered into an agreement with a new distributor who will make the company's protein sequencing instrument, Platinum® available for the first time in Japan. TOMY Digital Biology Co., Ltd., a renowned importer and distributor with a rich history dating back to the 1950s, will distribute Quantum-Si's next-generation protein sequencer™ and associated consumables throughout Japan. "Working with Quantum-Si marks a pivotal moment for TOMY Digital Biology, aligning with our commitment to advancing life sciences. We're poised to empower Japanese researchers wit

      1/18/24 8:30:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $QSI
    SEC Filings

    See more
    • Quantum-Si Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Quantum-Si Inc (0001816431) (Filer)

      4/10/25 4:49:41 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • SEC Form DEFA14A filed by Quantum-Si Incorporated

      DEFA14A - Quantum-Si Inc (0001816431) (Filer)

      3/20/25 4:12:20 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • SEC Form DEF 14A filed by Quantum-Si Incorporated

      DEF 14A - Quantum-Si Inc (0001816431) (Filer)

      3/20/25 4:07:34 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials